Comparison of Metabolic Deterioration between Insulin Analog and Regular Insulin after a 5-Hour Interruption of a Continuous Subcutaneous Insulin Infusion in Type 1 Diabetic Patients1
- 1 August 1999
- journal article
- clinical trial
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 84 (8), 2673-2678
- https://doi.org/10.1210/jcem.84.8.5912
Abstract
An interruption of continuous sc insulin infusion (CSII) of the insulin analog lispro should result in a more rapid metabolic deterioration of type 1 diabetic patients because of its pharmacokinetic characteristics. We analyzed the metabolic changes occurring during a 5-h interruption of CSII and the 5 h after restarting the pump in 10 type 1 diabetic patients. The study was a randomized, cross-over, open label design comparing insulin analog [Lispro (LP)] and regular insulin [Velosuline (VE)]. Plasma glucose, free insulin, glucagon,β -hydroxybutyrate (β-OHB), and nonesterified fatty acids (NEFA) were measured every hour from 0700 h (time zero) to 1700 h (600 min). After stopping CSII, the plasma glucose level was significantly higher in the LP group than in the VE group (P < 0.05–0.01). The plasma free insulin level decreased significantly with the two treatments, but was significantly lower with LP than with VE (P < 0.05–0.01). Plasma NEFA increased more rapidly and was significantly higher in the LP group than in the VE group (P < 0.01–0.05). Plasma β-OHB increased earlier with LP, but was not statistically different between the treatments. After restarting the pump, plasma glucose decreased with LP, but continued to increase with VE, and the plasma free insulin peak occurred earlier and was greater with LP than with VE (P < 0.05). Plasma NEFA and β-OHB levels decreased significantly with the two treatments, but more dramatically with LP treatment. Thus, a short interruption of Lispro in CSII is associated with an earlier, greater metabolic deterioration, but Lispro corrected this metabolic deterioration more effectively.Keywords
This publication has 20 references indexed in Scilit:
- Improvement of HbA1c and Blood Glucose Stability in IDDM Patients Treated With Lispro Insulin Analog in External PumpsDiabetes Care, 1998
- Blood glucose control on Sunday in IDDM patients: intensified conventional insulin therapy versus continuous subcutaneous insulin infusionDiabetes Research and Clinical Practice, 1998
- Reduced Frequency of Severe Hypoglycemia and Coma in Well-Controlled IDDM Patients Treated With Insulin LisproDiabetes Care, 1997
- Insulin LisproNew England Journal of Medicine, 1997
- Insulin Lispro in CSII: Results of a Double-Blind Crossover StudyDiabetes, 1997
- Reduction of Postprandial Hyperglycemia and Frequency of Hypoglycemia in IDDM Patients on Insulin-Analog TreatmentDiabetes, 1997
- Reduction in Severe Hypoglycemia With Long-Term Continuous Subcutaneous Insulin Infusion in Type I DiabetesDiabetes Care, 1996
- Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodesExperimental and Clinical Endocrinology & Diabetes, 1996
- Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDMDiabetologia, 1994
- [Lys(B28), Pro(B29)]-Human Insulin: A Rapidly Absorbed Analogue of Human InsulinDiabetes, 1994